Associations of C-reactive protein (CRP) and fibrinogen with death may weaken over time. Combining both markers may improve prediction of death in older adults. In 5,828 Cardiovascular Health Study participants (United States, 1989, 383 deaths (183 cardiovascular disease (CVD)) in years 1-3 (early) and 914 deaths (396 CVD) in years 4-8 (late) occurred. For men, when comparing highest to lowest quartiles, hazard ratios for early death were 4.1 (95% confidence interval (CI): 2.7, 6.3) for CRP and 4.1 (95% CI: 2.7, 6.4) for fibrinogen in models adjusted for CVD risk. For early CVD death, hazard ratios were 4.3 (95% CI: 2.2, 8.4) and 3.4 (95% CI: 1.8, 6.3), respectively. When comparing men in the highest quartiles of both biomarkers with those in the lowest, hazard ratios were 9.6 (95% CI: 4.3, 21.1) for early death and 13.5 (95% CI: 3.2, 56.5) for early CVD death. Associations were weaker for late deaths. For women, CRP (hazard ratio ¼ 2.3, 95% CI: 1.4, 3.9), but not fibrinogen (hazard ratio ¼ 1.3, 95% CI: 0.8, 2.2), was associated with early death. Results were similar for CVD death. Neither was associated with late deaths. CRP and fibrinogen were more strongly associated with death in older men than women and more strongly associated with early than late death. Combining both markers may identify older men at greatest risk of near-term death.
Inflammatory biomarkers such as C-reactive protein (CRP) and fibrinogen independently predict cardiovascular disease (CVD) and death in both middle-aged and older adults (1) (2) (3) (4) (5) . In the Physicians Health Study and the Honolulu Heart Program, CRP predicted myocardial infarction up to and beyond 10 years after measurement, with little change in risk over time (6, 7) . However, in other studies primarily in older people, the prognostic value of CRP appeared to be more pronounced for CVD events and death that occurred within 2-3 years of measurement than for later events (1, 8, 9) . Similar results were reported for fibrinogen in men in the Cardiovascular Health Study. Fibrinogen was more strongly associated with death within 2 years of measurement than with later death (10) .
In addition, sex-specific associations of inflammatory markers with cardiovascular events may exist. Fibrinogen independently predicted incident coronary heart disease in men in the Cardiovascular Health Study but was not associated with coronary heart disease or death in women (10) . There are both age-and sex-dependent differences in morbidity and mortality for CVD and sex differences in cytokine production after acute injury (11) as well as intrinsic sex differences in cardiac muscle physiology and biochemistry (12) . Other inflammatory conditions such as sepsis and trauma are also associated with sex-dependent outcomes (11) .
Most studies of inflammatory markers have examined individual markers. However, the use of a single biomarker may not represent true inflammatory burden, especially in older adults. Many inflammatory molecules are involved in atherosclerosis, and not all biomarkers reflect the same underlying pathophysiology. A combination of biomarkers may therefore improve risk prediction. Both biovariability and reproducibility of assay method also need to be considered. Very little is known about the biovariability of many inflammatory cytokines, and many assays are not highly reproducible. Of the markers studied to date, only CRP meets both criteria (13) . Fibrinogen levels show large interindividual variability, although the clinical fibrinogen assay is highly reproducible, eliminating some of the variation in the assay (13) . Other markers such as interleukin-6 show less interindividual variability, but assays themselves are highly variable, with coefficients of variation in the range of 15 percent (13) .
We examined the ''proximate pathophysiology'' of inflammatory burden (14) in older adults in the Cardiovascular Health Study by using CRP alone and combined with fibrinogen and other inflammatory markers (interleukin-6, albumin, and white blood cell count) to simultaneously assess prediction of total and CVD death 3 years from measurement (early) and >3 years after measurement (late). We also examined potential sex-specific associations of markers with death. We hypothesized that individual markers would be more strongly associated with proximate deaths than deaths distant in time and that associations would be larger considering the joint effects of the two markers.
MATERIALS AND METHODS

Cardiovascular Health Study
The Cardiovascular Health Study design has been reported previously (15) . A total of 5,201 adults aged 65 years (original cohort) were recruited from 1989 to 1990. An additional 687 African Americans aged 65 years (minority cohort) were recruited between 1992 and 1993. Baseline examinations included lifestyle and medical history, physical examination, blood collection, resting 12-lead echocardiography, ankle-brachial blood pressure index, and carotid ultrasonography. Prevalence and extent of clinical CVD (confirmed angina, myocardial infarction, or stroke) were assessed (15) . All subjects gave informed consent for participation in the study, and all procedures were conducted under institutionally approved protocols for use of human subjects.
Ascertainment of death
Original and minority cohorts were followed for 8 (mean, 6.9; standard deviation (SD), 1.7) and 5 (mean, 4.1; SD, 0.8) years, respectively. Deaths were ascertained by review of local obituaries and contact with proxies for those who died. Cause of death was adjudicated by using published criteria (16) . CVD death was defined as death due to atherosclerotic coronary heart disease, cerebrovascular disease, atherosclerotic disease, or other CVD. There was 100 percent complete ascertainment of death status.
Definitions
Body mass index was defined as weight (kg)/height (m 2 ). Smoking was classified as current, former (no smoking in the previous 30 days), or never. Diabetes was classified by American Diabetic Association guidelines (17) . In those free of clinical CVD at baseline, subclinical CVD was defined as the presence of at least one of the following: anklebrachial blood pressure index 0.9, maximum common or internal carotid artery intima media thickness 80th percentile, carotid artery stenosis 25 percent, major electrocardiography abnormalities, or positive response for angina or intermittent claudication on the Rose questionnaire (18) . Early deaths were deaths that occurred within the first 3 years of follow-up. Deaths that occurred after 3 years of follow-up were defined as late.
Laboratory methods
Blood collection, laboratory methods, and fibrinogen measurement (coefficient of variation ¼ 2.9 percent) have been reported (19) . CRP was measured in a high-sensitivity assay developed in-house (coefficient of variation ¼ 8.9 percent) (20) . All assays were conducted by using baseline blood samples. CRP and fibrinogen were measured in 5,806 and 5,788 subjects, respectively. In analyses of CRP and fibrinogen, 5,828 subjects with at least one biomarker measurement were included. Other inflammatory markers were also measured in baseline blood samples. Albumin (19) (n ¼ 5,807), white blood cell count (19) (n ¼ 5,793), and interleukin-6 (21) (n ¼ 5,382) levels were available for 5,828 participants selected for this study. and decreased albumin individually were significantly associated with risk of total and CVD death in these Cardiovascular Health Study participants, as expected. When combinations of markers were examined, fibrinogen and interleukin-6 were mutually exclusive in all models tested. Decreased albumin was associated with risk of all-cause death but not significantly associated with risk of CVD death when CRP and fibrinogen were included in the models. Further examination of the biomarker combinations revealed that CRP, fibrinogen, and their interaction were significantly associated with both total and CVD death. There were no significant interactions between CRP and white blood cell count or between fibrinogen and white blood cell count for total or CVD death. CRP and fibrinogen were therefore chosen for additional analyses.
We fit Cox proportional hazards to model CRP and fibrinogen, both in quartiles and continuously, to examine associations of these biomarkers with death. CRP and fibrinogen were also modeled simultaneously to investigate joint effects of the two markers. We used extended Cox models with time-varying covariates to allow hazard ratios to differ for events prior to and after 3 years of follow-up and to formally test for differences. Hazard ratios were adjusted for age, body mass index, total cholesterol, diabetes, systolic blood pressure, smoking, race, and clinic site. Hazard ratios were also adjusted for clinical CVD at baseline and subclinical CVD among those free of clinical CVD. Results were reported as hazard ratios with 95 percent confidence intervals. Analyses were stratified by gender to investigate potential sex-specific interactions.
In secondary analyses, we examined the impact of hormone replacement therapy in women since hormone replacement therapy use is associated with significant changes in marker levels. We likewise examined the impact of aspirin and other nonsteroidal antiinflammatory drugs. Statin use was not included in the model because only 1.9 percent of the original cohort and 4.3 percent of the minority cohort were using statins at baseline (23) .
To determine whether associations of biomarkers with total and/or CVD death were limited to younger or older Cardiovascular Health Study participants, analyses were also performed stratified on the median age of participants in this study (73 years). A total of 2,097 women and 1,456 men were aged 73 years at baseline; 1, 251 women and 1,024 men were aged 74 years at baseline.
RESULTS
Baseline risk factors and death during follow-up
Baseline characteristics by CRP and fibrinogen levels are shown in table 1. There were 1,297 total deaths (579 CVDrelated deaths). A total of 4,531 participants were alive at the end of follow-up. In the 2,480 men in the Cardiovascular Health Study, 236 deaths occurred in the first 3 years (early) and 501 late deaths occurred. Of the 236 early deaths, 110 were CVD related; 13 were due to fatal myocardial infarction. Of the 501 late deaths, 223 were CVD related; 17 were due to fatal myocardial infarction. In the 3,348 women in the Cardiovascular Health Study, there were 147 early and 413 late deaths. Of the 147 early deaths, 73 were CVD related; five were due to fatal myocardial infarction. Of the 413 late deaths, 173 were CVD related; 18 were due to fatal myocardial infarction.
Associations of CRP and fibrinogen with early death
Among men, hazard ratios for total early death were similar for CRP and fibrinogen quartiles (table 2), and both were associated with increased risk of total early death in unadjusted and adjusted models. When modeled together to assess their joint effects, CRP, fibrinogen, and their interaction were significantly associated with total early death in both unadjusted and adjusted models. Hazard ratios were 1. Among women, CRP and fibrinogen were associated with risk of total early death in unadjusted models (table 2) . After adjustment, associations diminished (table 2). After our adjustments, women in the highest quartile of CRP, but not fibrinogen, were at increased risk of total early death (table 2) . When modeled together, CRP, fibrinogen, and their interaction were significantly associated with total early death in unadjusted and adjusted models. Hazard ratios were 1.31 (95 percent CI: 1.10, 1.57) for CRP and 1.20 (95 percent CI: 1.00, 1.45) for fibrinogen in adjusted models. The interaction term was 0.85 (95 percent CI: 0.75, 0.96). Women in the highest quartile of CRP, but not fibrinogen, were at increased risk of early CVD death in adjusted models (table 2) . CRP, fibrinogen, and their interaction were marginally associated with early CVD death after adjustment (p ¼ 0.08). Hazard ratios were 1.31 (95 percent CI: 1.00, 1.71) for CRP and 1.23 (95 percent CI: 0.95, 1.61) for fibrinogen. The interaction term was 0.81 (95 percent CI: 0.66, 1.00).
Associations of CRP and fibrinogen with late death
Among men, hazard ratios for total late death were similar for CRP and fibrinogen quartiles, and both were associated with risk of total late death in unadjusted and adjusted models (table 3) . Associations were weaker for late than for early total death. When modeled together, there was significant interaction between CRP and fibrinogen (p ¼ 0.035) in the unadjusted model of late total death. The interaction did not remain significant upon adjustment (p ¼ 0.078), indicating that the joint effect of the markers in the adjusted model was marginal. Hazard ratios were 1.15 (95 percent CI: 1.00, 1.31) for CRP and 1.09 (95 percent CI: 0.98, 1.20) for fibrinogen in the adjusted model. The interaction term was 0.96 (95 percent CI: 0.92, 1.00). Hazard ratios for late CVD death (table 3) were similar for both markers in quartile models, and both remained significant predictors following adjustment (table 3) . When interactions between the markers were examined, hazard ratios were 1.25 (95 percent CI: 1.02, 1.53) for CRP and 1.21 (95 percent CI: 1.04, 1.40) for fibrinogen. The interaction term, 0.94 (95 percent CI: 0.88, 1.00), was marginally significant in the adjusted model.
Among women, CRP and fibrinogen were associated with increased risk of total late death in unadjusted models (table 3) . After adjustment, only CRP was significant ( 
Comparisons of the associations with early and late death
Using extended Cox models, we estimated hazard ratios for early and late events simultaneously for both CRP and fibrinogen. In adjusted models, increasing levels of markers were associated with increased risk of early total death and were weakly associated with late total death among men (figure 1). Hazard ratios for late total death for CRP and fibrinogen were significantly lower than those for early death (p ¼ 0.002 and p < 0.001 for the respective comparisons). Increasing levels of CRP and fibrinogen were also associated with increased risk of early CVD death and weakly associated with increased risk of late CVD death (figure 2). Hazard ratios for late CVD death for CRP were significantly lower than those for early CVD death (p ¼ 0.019). Hazard ratios for late CVD death for fibrinogen were marginally lower than those for early death (p ¼ 0.052). Among women, hazard ratios for total death for fibrinogen were not significantly different between early and late deaths (p ¼ 0.377) (figure 3). Hazard ratios for late total death for CRP were marginally lower than those for early death (p ¼ 0.059). Hazard ratios for CRP and fibrinogen were not significantly different when early and late CVD deaths were compared (p > 0.75) (figure 4). In models investigating all three effects, gender by early/late time by CRP and fibrinogen interactions, the omnibus tests of these interactions were highly significant (p < 0.001) for both total and CVD death.
Excluding women using hormone replacement therapy at baseline or adjusting for use of aspirin or other nonsteroidal antiinflammatory drugs in men and women did not significantly change our findings. The change in hazard ratios was 2 percent.
Combined association of CRP and fibrinogen with early death
Among men, hazard ratios for early total death increased with increasing CRP and fibrinogen, with a hazard ratio of 9.56 (95 percent CI: 4.34, 21.1) for those in the highest quartiles of both CRP and fibrinogen after adjusting for risk factors (figure 5). The hazard ratio for early CVD death associated with being in the highest quartiles of both markers compared with the lowest was 13.45 (95 percent CI: 3.20, 56.5; figure 6 ).
To determine whether the strong associations of CRP and fibrinogen with early death were limited to younger or older participants in the Cardiovascular Health Study, we performed analyses stratified on median baseline age (73 years). Among men aged 65-73 years at baseline, there were 96 early deaths (41 CVD related). Those in the highest quartiles of both CRP and fibrinogen compared with those in the lowest quartiles were at increased risk of early total and CVD death. Adjusted hazard ratios were 4.82 (95 percent CI: 1.60, 14.5) and 9.03 (95 percent CI: 1.14, 71.7), respectively. When we examined both markers individually and compared those in the highest with the lowest quartiles, adjusted hazard ratios for early total death were 4 Analyses combining CRP and fibrinogen did not reveal consistent trends for either total death (figure 7) or CVD death (figure 8) in women. In adjusted analyses, the hazard ratios for early total and CVD death for women in the highest quartiles of both markers compared with the lowest were 1.50 (95 percent CI: 0.73, 3.10) and 1.44 (95 percent CI: 0.80, 2.59), respectively. 
DISCUSSION
The major findings of this population-based study of older men and women were that 1) prediction of death, both total and CVD related, using CRP or fibrinogen was significantly stronger for early death occurring within 3 years of marker measurement than for later death; 2) among men, this association was largely independent of CVD risk factors while in women, adjustment tended to weaken the association; and 3) CRP and fibrinogen were independent predictors of death, and the joint effect of both markers provided enhanced ability to identify men at high risk of near-term death. Fibrinogen quartile 1 FIGURE 5. Adjusted hazard ratios associated with combined C-reactive protein (CRP) and fibrinogen quartiles for early total death in men, Cardiovascular Health Study, United States, 1989-2000. Adjustments were cholesterol, body mass index, systolic blood pressure, smoking, diabetes, age, race, and clinical and subclinical cardiovascular disease. Those whose CRP and fibrinogen levels were in the first quartile were the reference group (leftmost column). Fibrinogen quartile 1 FIGURE 6 . Adjusted hazard ratios associated with combined C-reactive protein (CRP) and fibrinogen quartiles for early cardiovascular disease death in men, Cardiovascular Health Study, United States, 1989-2000. Adjustments were cholesterol, body mass index, systolic blood pressure, smoking, diabetes, age, race, and clinical and subclinical cardiovascular disease. Those whose CRP and fibrinogen levels were in the first quartile were the reference group (leftmost column).
Our study confirmed the concept of an association of inflammation biomarkers with risk of death in older adults (1, 4, 9, 10, 24) . However, the time dependency of death prediction in this study is striking and considerably greater than the relatively weak time-dependent prediction of CVD events reported previously (1, 8, 9, 25, 26) . Other studies did not identify any time dependency (6, 24, 27) . Differences in time dependency between studies may be due to the outcomes being assessed. Our findings are specific for death since, in the Cardiovascular Health Study, we did not observe a significant time dependency when the association of CRP with myocardial infarction was examined (28) . Disparities among studies also may be due to differences in the age of participants, health status and behaviors, duration of follow-up, and/or extent or type of underlying atherosclerosis. For example, the Honolulu Heart Program studied elderly Fibrinogen quartile 1 FIGURE 7. Adjusted hazard ratios associated with combined C-reactive protein (CRP) and fibrinogen quartiles for early total death in women, Cardiovascular Health Study, United States, 1989-2000. Adjustments were cholesterol, body mass index, systolic blood pressure, smoking, diabetes, age, race, and clinical and subclinical cardiovascular disease. Those whose CRP and fibrinogen levels were in the first quartile were the reference group (leftmost column). Japanese-American men only (4) , and the Iowa 65þ Rural Health Promotion Project comprised very high-functioning, older men and women (1) .
It is possible that our findings represent a survivor effect and not necessarily a change in inflammation burden over time. Through genes, environment, and/or their interactions, some persons may suffer more detrimental effects from a high inflammatory burden than others do. The diminished risk of death after 3 years may reflect a depletion of those with the highest biomarker levels who are most susceptible to inflammation-related morbidity and mortality.
Alternatively, there may be changes in inflammatory processes over time, with increased inflammation leading to increased risk of death. In support of the latter possibility, age likely modifies the associations of inflammatory markers with CVD and death. CRP and fibrinogen predict CVD events in both older and middle-aged men and women (1, 10, 28, 29) ; however, the relative risks for older people appear lower than for younger people and lower for older women than for older men (28) . One reason for this finding may be that there are fundamental differences in underlying pathology between younger and older people. The frequency of finding a thrombus at autopsy decreases from greater than two thirds in younger men dying from sudden cardiac death to less than one third in older men (30) .
In the face of autopsy and epidemiologic data, we hypothesize that, in younger individuals, in the absence of other major disease processes, inflammatory biomarkers reflect the progression toward vascular lesions and therefore yield both short-and long-term prediction, much as cholesterol does. However, in older people, inflammation biomarkers may reflect the degree of complex advanced vascular disease burden, as well as other morbidities, with the highest levels reflecting severe pathology associated with early risk. Even within the older cohort of the Cardiovascular Health Study, we saw an age-related difference in the joint effect of CRP and fibrinogen in the prediction of death. For men aged 65-73 years at baseline, combining CRP and fibrinogen enhanced prediction of near-term CVD death but not near-term all-cause death. For men who were 74 years or older at baseline, combining CRP and fibrinogen enhanced prediction of both near-term CVD and all-cause death.
The much weaker association of CRP and fibrinogen with death among women in the Cardiovascular Health Study may reflect different pathophysiology in men and women. There are gender-related differences in cardiac muscle physiology and biochemistry (12) . Major risk factors are generally similar between men and women early in life, but they differ later in life. For example, women with obstructive coronary artery disease have more severe disease and disability than men do (31) . There are also gender differences in presentation and detection of CVD (31) and differences in CVD morbidity and mortality (11) . In addition, studies have reported gender differences in cytokine production after trauma (11) and differences in morbidity and mortality in inflammatory conditions other than CVD (12) . Women may differ from men in their susceptibility to the effects of increased inflammation as well. Hormone replacement therapy use did not appear to account for the gender-specific prediction in the current study. Although hormone replacement therapy affects levels of fibrinogen and CRP (32), only 2.3 percent of women in this study were using hormone replacement therapy at baseline, and excluding these women from analyses did not significantly change the results.
Our study, like others, is potentially limited by the use of a single biomarker measurement that contains both analytical and within-subject (i.e., day-to-day) variance. However, this factor would likely bias results toward the null. Therefore, we attempted to more accurately place study participants in the proper strata by using a combination of biomarkers to represent inflammatory burden. The MacArthur Research Network on Successful Aging Community Study (14) used four biomarkers-total cholesterol, albumin, CRP, and interleukin-6-to reflect inflammatory burden. Study participants with abnormal levels of three or four of the markers were at substantially increased risk of death, while those with abnormal levels of only one or two of the markers were at a slightly increased risk of death compared with those whose levels of markers were in the healthy reference range (14) . We examined five biomarkers for this study: CRP, fibrinogen, albumin, interleukin-6, and white cell count. Of these, CRP and fibrinogen provided independent and complimentary information and were the most significantly associated with risk of death. In addition, it is likely that CRP and fibrinogen represent different aspects of inflammation. CRP mediates foam cell uptake of plasma lipids (33) , activates the complement cascade (34) , and may impact monocyte and endothelial cell functions (35, 36) . Elevated levels of fibrinogen are associated with plasma viscosity and may contribute to increased platelet cross-linking and increased fibrin formation (37) . Both CRP and fibrinogen may be in the causal pathway of atherosclerosis, which, in turn, contributes to death through a variety of mechanisms.
Currently, a limited number of biomarkers are readily measured clinically (13) . In the future, we anticipate using multianalyte panels to quickly and efficiently measure aspects of many different pathways involved in atherosclerosis and other disease processes. Measuring multiple markers by using well-characterized assays will likely improve our ability to predict events in women as well. For example, soluble intracellular adhesion molecule-1, a marker of endothelial perturbation, was more predictive of events in women than in men in the Cardiovascular Health Study cohort (38) . Future studies may need to incorporate gender-specific marker panels to best assess risk of events.
Biomarkers that identify those at the greatest risk of nearterm morbidity and mortality will be useful clinically in targeting aggressive interventions. In particular, interventions to reduce inflammatory burden will likely impact a variety of pathophysiologic processes. Much focus has been on pharmacologic interventions such as aspirin and statins. However, lifestyle interventions such as increased physical activity may also reduce inflammation (39) (40) (41) . Large clinical trials, especially among women, are needed to determine appropriate interventions, measure effects of reducing inflammatory burden on clinical outcomes, and determine the necessary intensity and duration of treatment to maximize the benefit of specific interventions.
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In summary, we report that the inflammatory biomarkers CRP and fibrinogen were associated with death, particularly death within 3 years of biomarker measurement, in older men and women. The associations were stronger among men than women, and prediction of death in men was improved when both markers were combined. Our data support further exploration of the use of multiple biomarkers in assessing inflammation status and risk of morbidity and mortality.
